Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QLT Photofrin lung cancer promotions to begin in second quarter; FDA clears narrow new indication.

Executive Summary

QLT PHOTOFRIN LUNG CANCER PROMOTIONS TO BEGIN IN SECOND QUARTER 1998, following FDA clearance Jan. 9 for the photodynamic treatment of microinvasive non-small cell lung cancer. Photofrin is marketed in the U.S. by Sanofi for palliation of obstructing esophageal cancer. The supplemental indication, while narrow, gives QLT a position in the lung cancer therapy market. Photofrin (photodynamic porfimer) is now indicated "for use in photodynamic therapy for the treatment of microinvasive endobronchial non-small cell lung cancer in patients for whom surgery and radiotherapy are not indicated," labeling states.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel